Innovent Biologics, Inc. (“Innovent”), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announces that phase 1b study results of mazdutide (IBI362), a glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist, in Chinese patients with type 2 diabetes have been published in Nature Communications1. Professor Hongwei Jiang from the First Affiliated Hospital of Henan University of Science and Technology is the first author of the article. Professor Wenying Yang from China-Japan Friendship Hospital and Dr. Lei Qian are the corresponding authors.
Also Read: Slingshot Biosciences, Inc. Partners With Almog Diagnostic to Distribute Synthetic Cells Throughout
This randomized, double-blind, placebo-controlled multiple-ascending-dose phase 1b study (ClinicalTrials.gov: NCT04466904) evaluated the safety, tolerability and pharmacokinetics/ pharmacodynamics of IBI362 in Chinese patients with type 2 diabetes, with dulaglutide as an active control. Fourteen patients were enrolled in each of the three cohorts and randomized 8:4:2 to receive once weekly IBI362, placebo or 1.5 mg dulaglutide subcutaneously for 12 weeks. Dose escalation regimens for IBI362 and placebo were 1.0-2.0-3.0 mg (cohort 1), 1.5-3.0-4.5 mg (cohort 2) or 2.0-4.0-6.0 mg (cohort 3), with each dose level administered for 4 weeks.
IBI362 was well tolerated and showed multiple benefits of blood glucose control, weight loss and metabolic profiles.
- The most commonly-reported TEAEs were diarrhea (29.2%), decreased appetite (25.0%) and nausea (16.7%). Most gastrointestinal adverse events (diarrhea, nausea and vomiting) were mild in severity and transient. No severe treatment-emergent adverse event (TEAE) was reported.
- Least squares mean changes from baseline to week 12 in HbA1c levels were −1.46%, −2.23% and −1.66% for patients receiving IBI362 in cohort 1,2 and 3, respectively (−1.98% for dulaglutide).
- Least squares mean percent changes from baseline to week 12 in body weight were −0.9%，−5.0% and −5.4% for patients receiving IBI362 in cohort 1,2 and 3, respectively (−0.9% for dulaglutide).
- Reductions in waist circumference, body mass index, blood pressure and lipid levels, as well as improvement on insulin sensitivity were observed in patients receiving IBI362, with overall trends similar with those observed in phase 1b study in participants with overweight or obesity2.
Professor Wenying Yang of China-Japan Friendship Hospital, primary investigator of the study, stated: “In recent years, GLP-1R agonists with significant glycemic control effect and multiple benefits have gained increasing attention and recommendation by both domestic and international clinical practice guidelines. We are pleased to see that IBI362, a novel GLP-1R and GCGR dual agonist, is well tolerated and safe in Chinese patients with type 2 diabetes and preliminarily exhibits effects on blood glucose reduction and body weight loss, together with multiple metabolic benefits. The results of this study got published in Nature Communications, indicating that the capability of Chinese investigators and domestic enterprises in the early clinical development of innovative drugs in the field of metabolism has been receiving international recognition. I look forward to the results of the phase II clinical study of IBI362 in Chinese subjects with type 2 diabetes, and hope that IBI362 will succeed in the upcoming phase III studies and benefit the patients as soon as possible.”